Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases

This study has been terminated.
(slow accrual)
Information provided by (Responsible Party):
Comprehensive Cancer Center of Wake Forest University Identifier:
First received: March 12, 2008
Last updated: November 22, 2013
Last verified: November 2013

RATIONALE: Paricalcitol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. It may also stop the growth of tumor cells in bone.

PURPOSE: This phase II trial is studying how well paricalcitol works in treating patients with advanced prostate cancer and bone metastases.

Condition Intervention Phase
Metastatic Cancer
Prostate Cancer
Drug: paricalcitol
Other: immunoenzyme technique
Other: laboratory biomarker analysis
Procedure: dual x-ray absorptometry
Procedure: quality-of-life assessment
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Primary Purpose: Treatment
Official Title: Phase II Trial of Zemplar (19-nor-1 a,25-Dihydroxyvitamin D2, Paricalcitol Capsule) on Bony Remodeling in Advanced Androgen-Insensitive Prostate Cancer

Resource links provided by NLM:

Further study details as provided by Comprehensive Cancer Center of Wake Forest University:

Primary Outcome Measures:
  • Biochemical Markers (i.e., Serum Parathyroid Hormone [PTH], Bone-specific Alkaline Phosphatase, and Osteocalcin) That Are Surrogates for Fracture Risk and Are Associated With Increased Bone Pain, Morbidity, and Mortality From Prostate Cancer [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]

Enrollment: 2
Study Start Date: January 2009
Estimated Study Completion Date: January 2014
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Detailed Description:



  • To explore the relationship between paricalcitol therapy and markers of bone formation in patients with androgen-refractory, advanced prostate cancer with bone metastases.


  • To explore the relationship between paricalcitol therapy and markers of bone resorption in these patients.

OUTLINE: Patients receive oral paricalcitol once daily for 10 weeks in the absence of unacceptable toxicity.

Patients undergo blood sample collection periodically to determine markers of bone formation and resorption by ELISA; parathyroid hormone (PTH) levels by immunometric assay; prostate-specific antigen (PSA) levels by immunoassay; and 25-hydroxyvitamin D and 1,25(OH)_2D levels by radioimmunoassay.

Patients also undergo a bone densitometry (DEXA scan) at baseline and at 10 weeks to assess changes in bone strength.

Quality of life is assessed prior to, during, and after completion of treatment. Questionnaires include the Pain Inventory, the Brief Pain Inventory, the Functional Assessment of Cancer Therapy-G (FACT-G), and the Analgesic Use Diary (Narcotic Pain Medication Logbook).

After completion of study treatment, patients are followed every 6 months for 1 year.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed advanced adenocarcinoma of the prostate

    - Radiographically proven bone metastasis from prostate cancer

  • Androgen refractory disease (including anti-androgen withdrawal)
  • Secondary hyperparathyroidism, defined as two parathyroid hormone (PTH) values > 70 pg/mL, 14 days apart
  • ECOG performance status 0-2
  • Leukocytes ≥ 3,000/μL
  • Absolute neutrophil count ≥ 1,500/μL
  • Platelets ≥ 100,000/μL
  • Total bilirubin normal
  • AST/ALT ≤ 2.5 times upper limit of normal
  • Creatinine clearance ≥ 60 mL/min
  • Calcium normal
  • 25-hydroxyvitamin D (25-OHD) ≥ 20 ng/mL
  • 1,25(OH)_2D normal
  • Patients with serum 25-OHD indicative of vitamin D insufficiency are eligible provided they are treated with ergocalciferol to raise 25-OHD levels to 20 ng/mL prior to paricalcitol therapy
  • More than 8 weeks since prior bisphosphonates
  • More than 2 weeks since prior palliative radiotherapy
  • More than 4 weeks since other prior therapy
  • No more than one prior taxane-containing chemotherapy regimen for metastatic disease
  • Multiple lines of prior therapy with hormonal agents allowed
  • Concurrent corticosteroids allowed provided the dose remains stable during the study period


  • Underlying metabolic bone disease or vitamin D deficiency
  • History of hypercalcemia
  • Concurrent uncontrolled illness or co-morbid condition (including psychiatric illness) that would interfere with study compliance
  • Concurrent ergocalciferol supplementation
  • Concurrent chemotherapy or hormonal therapy
  • Concurrent investigational or commercial agents for the malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00634582

United States, North Carolina
Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States, 27157-1096
Sponsors and Collaborators
Comprehensive Cancer Center of Wake Forest University
Study Chair: Gary G. Schwartz, MD, PhD, MPH Comprehensive Cancer Center of Wake Forest University
Principal Investigator: Mebea Aklilu, MD Comprehensive Cancer Center of Wake Forest University
  More Information

No publications provided

Responsible Party: Comprehensive Cancer Center of Wake Forest University Identifier: NCT00634582     History of Changes
Other Study ID Numbers: CDR0000583657, P30CA012197, CCCWFU-85107
Study First Received: March 12, 2008
Results First Received: November 22, 2013
Last Updated: November 22, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Comprehensive Cancer Center of Wake Forest University:
adenocarcinoma of the prostate
stage IV prostate cancer
recurrent prostate cancer
bone metastases

Additional relevant MeSH terms:
Neoplasm Metastasis
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site
Neoplastic Processes
Pathologic Processes
Prostatic Diseases
Urogenital Neoplasms processed this record on November 24, 2014